RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Mond

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday.

Shares of RCI Hospitality Holdings, Inc. (NASDAQ:RICK) rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results.

RCI Hospitality reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $73.23 million which beat the analyst consensus estimate of $72.98 million.

RCI Hospitality shares surged 15.4% to $60.16 on Tuesday.

Here are some other big stocks recording gains in today's session.

Quantum Computing Inc. (NASDAQ:QUBT) shares jumped 31.7% to $14.60 after the company announced it was awarded a prime contract by NASA to apply Dirac-3 for imaging and data processing support.
Akso Health Group (NASDAQ:AHG) shares surged 25.6% to $1.47.
Arqit Quantum Inc. (NASDAQ:ARQQ) shares gained 21.7% to $32.20.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) climbed 20% to $19.82 after the company and Sanofi announced that primary endpoints were met in the Phase 2b trial of Duvakitug for ulcerative colitis and Crohn’s disease.
Hesai Group (NASDAQ:HSAI) gained 20% to $12.16.
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) gained 17.8% to $12.10.
SelectQuote, Inc. (NYSE:SLQT) shares rose 17.3% to $3.2388.
Rezolve AI Limited (NASDAQ:RZLV) gained 15% to $2.4494.
Arqit Quantum Inc. (NASDAQ:ARQQ) rose 15% to $30.39.
SkyWater Technology, Inc. (NASDAQ:SKYT) gained 14.2% to $11.60.
Rigetti Computing, Inc. (NASDAQ:RGTI) gained 11.3% to $9.38.
GameStop Corp. (NYSE:GME) gained 5.3% to $31.01.
Bilibili Inc. (NASDAQ:BILI) rose 5% to $20.17.
Sanofi (NASDAQ:SNY) gained 4.8% to $48.08 after the company and Teva announced that primary endpoints were met in the Phase 2b trial of Duvakitug for ulcerative colitis and Crohn’s disease.
Tesla, Inc. (NASDAQ:TSLA) shares rose 3% to $477.19 after Mizuho upgraded the stock from Neutral to Outperform and raised its price target from $230 to $515.